Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: Jorgen Jensen who wrote (516)	3/16/1999 2:22:00 AM
From: Jorgen Jensen	Read Replies (1) \| Respond to of 4974

Hmm, I just read your original post for this thread, and the rules for posting here, and now realize that my previous message about Progen Ind. may not be appropriate for this forum. Well, I will await your reply. Be kind.

To: Jorgen Jensen who wrote (516)	3/16/1999 11:10:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4974

Jorgen: OK, I know the company. PI-88 is a heparanase inhibitor. I expect it to face the same issues with toxicity that RGEN faces with their efforts. Nonetheless, seems like a good effort to me. See the RGEN thread for more commentary? You were correct.... the news hit here this morning...... biz.yahoo.com Thanks! Rick

To: Jorgen Jensen who wrote (516)	3/19/1999 1:32:00 AM
From: scaram(o)uche	Respond to of 4974

OK, going over Tuesday and Wednesday, it looks like we have Progen and GMED for Tuesday, and zip for Wednesday. Progen..... interesting work, and a unique target. Let's wait to nominate it again when they show highly significant results from a phase II. One comment however.... I've been thinking about my comment re. RGEN-like issues concerning tox, and I don't think that's fair. I need to do more reading concerning the proposed mechanism. And GMED...... another good suggestion. However, I've never been particularly impressed with the rationale for using IFNalpha (or IL-2) in tumor systems. Let's also wait for phase II data here and nominate it after we see great results. Good suggestions, but I'd say that neither yet clears the hurdle. Other opinions are welcome.